NCT02767596

Evaluation of Lixisenatide Efficacy in Diabetes Mellitus Type 2 With Failure of Other GLP-1 Analog

A Pilot Single-Arm Open-Label Study to Evaluate the Efficacy of Treatment With Lixisenatide in Diabetes Mellitus Type 2 Patients With Failure of Other GLP-1 Analog

• Status: Terminated
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 2 (actual)
• Sponsor: Laniado Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The study aims to examine the effectiveness of the short acting GLP-1 analog, Lixisenatide to achieve glycemic control in type 2 diabetes patients, in patients with failure of long acting GLP-1 analog. Patients who fail to achieve significant improvement in diabetes control on basal insulin and Liraglutide will be switched to basal insulin and lixisenatide treatment for 12 weeks. The primary outcomes will be changes in HBA1C and weight.

Conditions

• Diabetes Mellitus Type 2

Interventions

Type	Name	Description
DRUG	Lixisenatide
DRUG	Basal insulins	patients are on basal insulin treatment

Timeline

• Start date: 2016-07-12
• Primary completion: 2017-02-01
• Completion: 2017-02-21
• First posted: 2016-05-10
• Last updated: 2017-04-07

Locations

1 site across 1 country: Israel